RU2020122659A - Комбинация антимускаринового или антихолинергического средства и липоевой кислоты и ее применения - Google Patents

Комбинация антимускаринового или антихолинергического средства и липоевой кислоты и ее применения Download PDF

Info

Publication number
RU2020122659A
RU2020122659A RU2020122659A RU2020122659A RU2020122659A RU 2020122659 A RU2020122659 A RU 2020122659A RU 2020122659 A RU2020122659 A RU 2020122659A RU 2020122659 A RU2020122659 A RU 2020122659A RU 2020122659 A RU2020122659 A RU 2020122659A
Authority
RU
Russia
Prior art keywords
acid
formula
lipoic
compound
pharmaceutically acceptable
Prior art date
Application number
RU2020122659A
Other languages
English (en)
Russian (ru)
Inventor
Махеш КАНДУЛА
Original Assignee
Целликсбио Прайвет Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Целликсбио Прайвет Лимитед filed Critical Целликсбио Прайвет Лимитед
Publication of RU2020122659A publication Critical patent/RU2020122659A/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2020122659A 2018-02-05 2019-02-05 Комбинация антимускаринового или антихолинергического средства и липоевой кислоты и ее применения RU2020122659A (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN201841004306 2018-02-05
IN201841004306 2018-02-05
IN201841008091 2018-03-05
IN201841008091 2018-03-05
PCT/IB2019/050901 WO2019150341A1 (en) 2018-02-05 2019-02-05 Combination of an antimuscarinic or an anticholinergic agent and lipoic acid and uses thereof

Publications (1)

Publication Number Publication Date
RU2020122659A true RU2020122659A (ru) 2022-03-09

Family

ID=67480013

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2020122659A RU2020122659A (ru) 2018-02-05 2019-02-05 Комбинация антимускаринового или антихолинергического средства и липоевой кислоты и ее применения

Country Status (13)

Country Link
US (2) US20200375961A1 (https=)
EP (1) EP3749303A4 (https=)
JP (1) JP2021512876A (https=)
KR (1) KR20200118128A (https=)
AU (1) AU2019214557A1 (https=)
BR (1) BR112020015436A2 (https=)
CA (1) CA3089894A1 (https=)
IL (1) IL276350A (https=)
MX (1) MX2020008173A (https=)
RU (1) RU2020122659A (https=)
SG (1) SG11202006492SA (https=)
WO (1) WO2019150341A1 (https=)
ZA (1) ZA202004058B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3522873B1 (en) * 2016-10-04 2022-03-16 Cellix Bio Private Limited Compositions and methods for the treatment of xerostomia
CA3116589A1 (en) 2018-10-26 2020-04-30 Ocuphire Pharma, Inc. Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders
WO2020144546A1 (en) * 2019-01-12 2020-07-16 Cellix Bio Private Limited Combination of selective alpha-adrenergic receptor agonist or an anticholinergic agent and lipoic acid and uses thereof
CN113387923A (zh) * 2020-03-13 2021-09-14 诺华股份有限公司 硫辛酸胆碱酯盐的药物组合物及使用其的治疗方法
IL298476A (en) * 2020-05-26 2023-01-01 Cellix Bio Private Ltd Pharmaceutical formulations of pilocarpine r-(+)-lipoate
WO2022080529A1 (ko) * 2020-10-15 2022-04-21 경상대학교병원 침분비 저하증 예방 또는 치료용 약학적 조성물 및 건강기능식품
WO2023052977A1 (en) * 2021-09-29 2023-04-06 Avaca Pharma Private Limited Compositions, methods and uses thereof
WO2023052974A1 (en) * 2021-09-29 2023-04-06 Avaca Pharma Private Limited Ocular compositions and methods for the treatment of ophthalmic diseases and disorders
CN119454701A (zh) * 2022-01-18 2025-02-18 苏州普乐康医药科技有限公司 一种含西维美林的眼用制剂及其制备方法和应用
EP4469047A4 (en) * 2022-01-25 2026-03-04 Biotheravision Inc AQUEOUS COMPOSITIONS OF CEVIMELINE AND METHODS OF USE
WO2023143575A1 (zh) * 2022-01-29 2023-08-03 南京济群医药科技股份有限公司 一种m-胆碱受体激动剂化合物及其制备方法和用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3608073A (en) * 1968-07-16 1971-09-21 Barnes Hind Pharm Inc Emulsion of pilocarpine for ophthalmic use
CN1960735B (zh) * 2004-05-20 2015-07-29 代阿麦迪卡股份有限公司 药物组合在治疗胰岛素抗性中的应用
JP2006070027A (ja) * 2004-08-06 2006-03-16 Dai Ichi Seiyaku Co Ltd 口腔粘膜投与剤
US20110150974A1 (en) * 2004-08-06 2011-06-23 Daiichi Pharmaceutical Co., Ltd. Agent For Oral Mucosal Administration
WO2007064755A2 (en) * 2005-11-30 2007-06-07 Endo Pharmaceuticals Inc. Treatment of xerostomia with a sulfur-containing antioxidant
UA86441C2 (ru) * 2007-03-30 2009-04-27 Акционерное Общество Открытого Типа "Галичфарм" (2-гидроксиэтил)триметиламмония тиоктат (холина тиоктат), имеющий гепатопротекторное, гипоаммониемическое и детоксицирующее действие, способ его получения, фармацевтическая композиция на его основе
US20090263467A1 (en) * 2008-04-21 2009-10-22 Hemant Narahar Joshi Combination drug therapy using orally dissolving film or orally disintegrating tablet dosage forms to treat dry mouth ailments
EP2821405B1 (en) * 2009-06-15 2016-04-13 Encore Health, LLC Choline esters for treating presbyopia and cataract
JP5595513B2 (ja) * 2009-11-12 2014-09-24 アカシア ファーマ リミテッド 口腔乾燥症の治療のためのベタネコールの使用
US10507245B2 (en) * 2012-07-19 2019-12-17 Luis Felipe Vejarano Restrepo Ophthalmic formulation and method for ameliorating presbyopia
JP2015533174A (ja) * 2012-10-11 2015-11-19 セラヴィダ,インコーポレイテッド ピロカルピンの医薬製剤
KR101586789B1 (ko) * 2012-12-28 2016-01-19 주식회사 종근당 양이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
US9427144B2 (en) * 2014-01-03 2016-08-30 Ophthalmx Llc Methods and systems for detecting ophthalmic disease
CA2936146A1 (en) * 2014-01-06 2015-07-09 Stealth Biotherapeutics Corp Methods and compositions for preventing or treating dominant optic atrophy
EP3522873B1 (en) * 2016-10-04 2022-03-16 Cellix Bio Private Limited Compositions and methods for the treatment of xerostomia
CA3081553C (en) * 2017-11-17 2022-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of eye disorders
WO2020144546A1 (en) * 2019-01-12 2020-07-16 Cellix Bio Private Limited Combination of selective alpha-adrenergic receptor agonist or an anticholinergic agent and lipoic acid and uses thereof

Also Published As

Publication number Publication date
BR112020015436A2 (pt) 2020-12-22
AU2019214557A1 (en) 2020-08-20
SG11202006492SA (en) 2020-08-28
US20200375961A1 (en) 2020-12-03
EP3749303A1 (en) 2020-12-16
US20230310391A1 (en) 2023-10-05
ZA202004058B (en) 2021-08-25
CA3089894A1 (en) 2019-08-08
WO2019150341A1 (en) 2019-08-08
MX2020008173A (es) 2020-09-25
IL276350A (en) 2020-09-30
JP2021512876A (ja) 2021-05-20
EP3749303A4 (en) 2022-01-26
KR20200118128A (ko) 2020-10-14

Similar Documents

Publication Publication Date Title
RU2020122659A (ru) Комбинация антимускаринового или антихолинергического средства и липоевой кислоты и ее применения
JP2021512876A5 (https=)
ES2743153T3 (es) Métodos para tratar el síndrome de fibromialgia
ES2927675T3 (es) Tratamiento de la cataplexia
JP2004526745A5 (https=)
ES2729713T3 (es) Compuestos tricíclicos, composiciones que los comprenden y usos de los mismos
AU2014209387A1 (en) Toxic aldehyde related diseases and treatment
ES2979262T3 (es) Composiciones que comprenden metilfenidato-profármacos, procesos de elaboración y uso de las mismas
RU2019113465A (ru) Композиции и способы лечения ксеростомии
ES2498681T3 (es) Derivados de ácidos grasos con alta palatabilidad para administración oral
RU2012142811A (ru) Фармацевтические композиции и пероральные дозированные формы пролекарства леводопы и способы применения
CN107074884A (zh) 活性剂的矿物质氨基酸复合物
JP2022191331A (ja) 炎症及び疼痛の治療のための組成物及び方法
TW201538155A (zh) 活性成份輔助組成物及將活性成份化合物遞送給對象之方法
JPWO2019150341A5 (https=)
JPWO2012074069A1 (ja) 新規化合物及びその医薬用途
JP2006503031A5 (https=)
JP2025023120A (ja) d-アンフェタミン化合物、組成物、ならびにそれを作製および使用するためのプロセス
US20170319519A1 (en) Combination for the treatment of conditions involving muscular pain
WO2016020919A1 (en) Compositions comprising tricyclic compounds, and uses thereof
RU2008134143A (ru) Фармацевтическая композиция цитиколина, холина альфосцерата и l-карнитина (или ацетил-l-карнитина) для лечения и профилактики заболеваний центральной нервной системы и способ лечения
CN109310669B (zh) 氨基甲酸酯化合物用于预防或治疗三叉神经痛的用途
RU2005138369A (ru) Фармацевтически полезные соли производных карбоновой кислоты
JP2005523269A5 (https=)
RU2019119103A (ru) Композиции и способы лечения инфекционных заболеваний ротовой полости